| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
11-04-2016, 11:02 AM
|
#1 | ||
|
|||
|
Member
|
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease - Full Text View - ClinicalTrials.gov
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease (PD Nilotinib) |
||
|
 Reply With Quote
|
|
11-05-2016, 02:02 AM
|
#2 | ||
|
|||
|
Member
|
I note that they say that this Nilotinib-for-PD trial (Phase 2 trial) is scheduled to start in January, and that recruitment has not yet commenced.
I got an email from GU earlier this week. In the email they said that for their Nilotinib trials they will only be recruiting patients who live within 50 miles of Georgetown University Hospital in Washington DC. |
||
|
|
Reply With Quote
|
| "Thanks for this!" says: | zanpar321 (11-06-2016) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Comparison of the pharmacokinetics of an oral extended-release capsule formulation of | Parkinson's Disease | |||
| Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Par | Parkinson's Disease | |||
| Long-term safety and tolerability of rotigotine... (Neupro) | Parkinson's Disease | |||
| fwiw, The Pharmacokinetics and Pharmacodynamics of Levodopa in the Treatment of Parki | Parkinson's Disease | |||
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parki
Linear Mode
